---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-041191"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2026-02-06T23:59:59+00:00"
generated_at: "2026-05-16T04:02:36.002486+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Nasdaq notifies Lyra Therapeutics of delisting; company deemed a public shell

## Summary
- Nasdaq cites public shell status after suspension of lead drug LYR-210 and near-complete workforce reduction.
- Nasdaq also cites non-compliance with minimum $2.5M equity listing rule.
- Company has requested hearing to appeal delisting; stay in effect pending panel decision.
- CEO and CFO now consultants; no ongoing operations after workforce reduction.

## SEC filing metadata
- accession: 0001193125-26-041191
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2026-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.95
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000119312526041191/0001193125-26-041191-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000119312526041191/d157841d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-041191
- JSON: https://secwatch.observer/filing/0001193125-26-041191.json
- Plain text: https://secwatch.observer/filing/0001193125-26-041191.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.